Scientist

POSITION SUMMARY

GPN Vaccines is seeking two motivated Scientists to support immunological testing. 

The Scientist is responsible for designing, executing, and documenting immunoassay-based experiments within a GCLP laboratory. The role supports clinical trial sample testing, method development, assay validation, and generation of high-quality data that meets regulatory standards.

KEY RESPONSIBILITIES

• Perform immunoassays as required.
• Handle clinical samples in alignment with GCLP and biosafety requirements.
• Develop and optimise immunoassays.
• Review and interpret data with attention to validity, trends and QC acceptance criteria.
• Ensure all results and reports meet GCLP standards, including audit-ready completeness, traceability and reproducibility.
• Perform validation and verification of analytical methods and instruments as needed.
• Prepare technical summaries, validation reports, and study documentation for internal and external stakeholders.
• Participate in internal and external audits by providing records and explaining procedures when needed.
• Report deviations, non-conformances, or equipment failures to the Laboratory Manager and Quality Assurance.
• Support quality improvement initiatives and contribute to ongoing GCLP compliance.
• Assist with instrument maintenance, calibration and performance monitoring.

Essential

• PhD in immunology, molecular biology, biochemistry, or related field
• Solid understanding of GCLP principles, documentation standards, and regulatory expectations.
• Proven capability in handling and processing clinical trial samples.

Desirable

• Experience validating immunoassays for clinical trial use. 
• Hands-on laboratory experience with immunoassays in an industry, CRO, or clinical testing environment.

• Exposure to LIMS, ELN, and GxP-compliant data systems.
• Familiarity with ICH guidelines, FDA/TGA/EMA expectations, and method lifecycle management.
• Flow cytometry panel design, cell culture, and functional assay experience.

Applications close 16th January 2026